Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
23 hedge funds and large institutions have $11.8M invested in Aevi Genomic Medicine Inc in 2013 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
58% more capital invested
Capital invested by funds: $7.43M → $11.8M (+$4.34M)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
5% more funds holding
Funds holding: 22 → 23 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$211K |
| 2 |
Morgan Stanley
New York
|
+$128K |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$116K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$69.6K |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$65.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.63M |
| 2 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
-$317K |
| 3 |
Renaissance Technologies
New York
|
-$58K |
| 4 |
CD
Carl Domino
West Palm Beach,
Florida
|
-$27.2K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$4.64K |
GNMX Hedge Fund Activity: Q3 2013 in Review
23 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q3 2013, worth a combined $11.8M — up 58% from $7.43M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GNMX positions and 4 closed out — a net gain of 1 holder — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $211K. The largest seller was Sabby Management, exiting entirely with an estimated $1.63M sold.
- 23 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q3 2013, up from 22 in Q2 2013.
- Funds reported $11.8M of Aevi Genomic Medicine Inc stock for Q3 2013, up 58% quarter-over-quarter.
- 5 funds opened new Aevi Genomic Medicine Inc positions in Q3 2013 and 4 closed out, a net change of +1 holder.
- The largest Aevi Genomic Medicine Inc buyer in Q3 2013 was Vanguard Group, an estimated $211K added.
- The largest Aevi Genomic Medicine Inc seller in Q3 2013 was Sabby Management, an estimated $1.63M sold.
Based on aggregated 13F filings for Q3 2013.